Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors Post published:November 18, 2024 Continue ReadingAlentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors
Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors Post published:November 12, 2024 Continue ReadingAlentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors
Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers Post published:October 2, 2024 Continue ReadingAlentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers
Alentis Appoints Jonathan Freve CFO Post published:September 3, 2024 Continue ReadingAlentis Appoints Jonathan Freve CFO
Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis Post published:May 29, 2024 Continue ReadingAlentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis
Alentis Announces Presentations on Claudin-1 in Fibrosis at the ERA and ATS Conferences Post published:May 14, 2024 Continue ReadingAlentis Announces Presentations on Claudin-1 in Fibrosis at the ERA and ATS Conferences
Alentis Sponsors 3rd International Summit on Lung Cancer Post published:May 2, 2024 Continue ReadingAlentis Sponsors 3rd International Summit on Lung Cancer
Alentis Appoints Alberto Toso Chief Scientific Officer Post published:April 29, 2024 Continue ReadingAlentis Appoints Alberto Toso Chief Scientific Officer
Alentis ´Shares Their Colors´ for Rare Disease Day 2024 Post published:February 29, 2024 Continue ReadingAlentis ´Shares Their Colors´ for Rare Disease Day 2024
William Pao Joins Alentis Therapeutics as Independent Board Member Post published:January 8, 2024 Continue ReadingWilliam Pao Joins Alentis Therapeutics as Independent Board Member
